Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Scheen has received lecturer/scientific advisor/clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and NovoNordisk, and has worked as a clinical investigator in the EMPA-REG OUTCOME, CANVAS-R, DECLARE-TIMI 58, LEADER and HARMONY Outcomes cardiovascular outcome trials
These findings may encourage clinicians to consider OSA status when selecting glucose-lowering therapy, particularly among high-risk cardiometabolic patients
Al-AttasOAl-DaghriNAlkharfyKAlokailMAl-JohaniNAbd-AlrahmanSet al
Toxicol Sci 65:166176 Jaeschke H, Knight TR, Bajt ML (2003) The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity
